Health knowledge made personal
Join this community!
› Share page:
Search posts:

Simple Direct Zirconium-89 Cell PET Label, 89Zr-Labeled Cells, and Methods for Real-time In Vivo Pet Imaging

Posted Jan 14 2013 7:00pm

Description of Invention:
The capability to image cells and cellular processes in real time over a scale of days could dramatically improve research insights and the effectiveness of cell-based therapies. Zirconium-89 (89Zr) has a half-life of over three days (78.4 hours) over 44 times longer compared to Fluorine (18F) the most commonly used PET isotope (half-life of 1 hour and 50 minutes). 89Zr is also advantageous compared to other long half-life isotopes because it is not limited by high background activity and cell toxicity. Labeling cells with 89Zr, is currently accomplished by indirect methods using secondary cell-type specific reagents such as antibodies. This technology is a PET imaging complex of 89Zr and polycation that is internalized by the cells. This complex has been able to directly label a wide range of cells, without the use of secondary reagents. 89Zr-labeled cells of lymphocytic lineage, including T cells, natural killer T-cells, macrophages, dendritic cells, and stem cells, have been produced and imaged in vivo with minimal damage to the cells. This PET imaging agent can be readily combined with an MR imaging agent for combined PET/MR imaging of cells. The imaging capabilities enabled by this technology may significantly improve cell therapies, cell level diagnostics and aid research for non-cell based therapies.

  • Imaging
  • Diagnostic
  • Cell therapies
  • Transplantation and transfusion

  • Direct labeled cells (versus indirect techniques)
  • Longer half-life
  • Not limited by high background activity and cell toxicity

Development Status:
  • Early-stage
  • Pre-clinical
  • In vivo data available (animal)

Omer Aras (CC)
Peter L Choyke (NCI)
Joseph A Frank (CC)
Jeremy M Pantin (NHLBI)
Noriko Sato (NHLBI)

Patent Status:
HHS, Reference No. E-056-2012/0
US, Application No. 61/611,964 filed 16 Mar 2012

Collaborative Research Opportunity:
The NCI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact John Hewes, Ph.D. at .

For Licensing Information Please Contact:
Edward (Tedd) Fenn
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-5031
Fax: 301-402-0220

Ref No: 2511

Updated: 01/2013

Post a comment
Write a comment:

Related Searches